Maksim Mamonkin, Ph.D.

Associate Professor

Email

mamonkin@bcm.edu

Positions

Associate Professor: Pathology & Immunology
Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX, US

Member: Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States

Education

PhD from Baylor College of Medicine: 10/2013 - Houston, Texas, United States

Professional Interests

Immunobiology of chimeric antigen receptor (CAR) T cells
Adoptive T cell therapy of cancer and autoimmune diseases
Clinical trials of CAR T cells in hematologic malignancies
Synthetic biology in cell therapies

Professional Statement

The main research interest of my laboratory is studying immunobiology of T-cells engineered with chimeric antigen receptors (CARs) and creating new cell therapies for devastating diseases. We investigate molecular mechanisms regulating the activity of CAR T-cells and develop new strategies for clinical translation. In particular, we are utilizing protein engineering and genome editing to create T-cell therapies against T-cell malignancies (T-ALL, T-cell lymphoma) with minimal damage to normal lymphocytes. We are also exploring new strategies to target pathogenic T-cells in the context of immune rejection and allo/autoimmune diseases. These therapies are being evaluated in Phase I clinical trials at BCM (NCT03081910, NCT03690011, NCT04219163).

Websites

VIICTR Publications List

Selected Publications

Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M.. " Engineered off-the-shelf therapeutic T cells resist host immune rejection " Nat Biotechnol. 2021 Jan 1;
Pubmed PMID: 32661440.
Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M. " CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. " Blood. 2017 Jul ;
Pubmed PMID: 28539325.
Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M.. " Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T-cells for T-cell malignancies. " Mol Ther. 2022 Sep 9;
Pubmed PMID: 36086817.
Mo F, Watanabe N, Ingersoll Omdahl K, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, Brenner MK, Tkachev V, Mamonkin M.. " Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. " Blood. 2022 Aug 31;
Pubmed PMID: 36044667.